News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase I
Daiichi Sankyo Cancer Enterprise Pipeline Data Showing Swift Progress In Precision Medicine For Breast Cancer To Be Presented At 2017 ASCO Annual Meeting 5/24/2017
CLJI Worldwide Trial Enrolls First Patient In Clinical Study Evaluating The Performance Of VIBLOK As A Barrier For Herpes Simplex Virus Transmission In Men And Women 5/24/2017
Seattle Children's Brings First-Of-Its-Kind Precision Medicine Clinical Trial To Inflammatory Bowel Disease, Bone Marrow Transplant Patients 5/24/2017
Spyryx Biosciences Reports Positive Data On SPX-101 At American Thoracic Society International Conference 5/24/2017
United Neuroscience Reports Positive Phase I Results For Active Vaccine UB-311 In Alzheimer’s Disease 5/23/2017
Aeglea (AGLE) Provides AEB1102 Program And Corporate Update 5/23/2017
6 (Plus 2!) Most Notable ASCO Abstracts So Far 5/22/2017
5 Biotechs Releasing Highly-Anticipated Data at ASCO 5/22/2017
Regeneus (RGS.AX) Positive Clinical Trial Results For Progenza 5/22/2017
Poxel (POXEL.PA) Presents Imeglimin Japanese Phase 1 Results And Mechanistic Data At The 9th Scientific Meeting Of The Asian Association For The Study Of Diabetes In Japan 5/22/2017
Adamas Pharma (ADMS) Presents Positive Phase Ia Data Of ADS-4101 (Lacosamide) For The Treatment Of Partial Onset Seizures In Epilepsy 5/22/2017
Shire (SHPG)'s Hemophilia A Drug Flunks Tiny Phase I Trial 5/22/2017
BioLineRx Announces Regulatory Submission For Phase Ib Trial Of BL-8040 In Combination With Atezolizumab In AML 5/22/2017
ZIOPHARM Oncology (ZIOP) Announces Results Of Ad-RTS-hIL-12 + Veledimex In Recurrent Glioblastoma To Be Presented At The 2017 ASCO Annual Meeting 5/19/2017
MorphoSys AG Announces First Results From Phase I Study With Lanthipeptide MOR107 In Healthy Volunteers 5/19/2017
Acura Pharma (ACUR) Initiates Second Clinical Study On LTX-04 5/19/2017
ADC Therapeutics Doses First Patient In A Phase I Clinical Trial Of ADCT-502 In Patients With Advanced Solid Tumors With HER2 Expression 5/19/2017
Deciphera To Report Phase I Clinical Study Results With DCC-2618 At The 2017 ASCO Annual Meeting 5/18/2017
Aileron Therapeutics Announces Oral Presentation At ASCO On ALRN-6924 Targeting p53 5/18/2017
bluebird bio (BLUE) To Present New Data From Lentiglobintm Clinical Studies At European Hematology Association (EHA) Annual Meeting 5/18/2017
Juno (JUNO) To Present Key Clinical Data Updates On JCAR017 And JCAR014 At The 2017 ASCO Annual Meeting 5/18/2017
ImmunoGen (IMGN) Announces New Clinical Data With Mirvetuximab Soravtansine In Ovarian Cancer To Be Presented At 2017 ASCO Annual Meeting 5/18/2017
New Clinical And Biomarker Data Validate Immune Design Corporation (IMDZ)’s Lead Programs And Discovery Platforms 5/18/2017
Symic Biomedical Announces Results From MODIFY-OA Trial Of SB-061 For The Treatment Of Osteoarthritis Of The Knee 5/18/2017
Data From Clinical Study Of NewLink Genetics (NLNK)’ IDO Pathway Inhibitor, Indoximod, To Be Presented At The 22nd European Hematology Association Congress 5/18/2017
Three Abstracts On Dosing Regimens Of Cellectar Biosciences  (CLRB)’s CLR 131 In A Variety Of Tumor Types Published In The 2017 ASCO Annual Meeting Proceedings 5/18/2017
ObsEva (OBSV) Announces The Completion Of A Phase I Drug-Drug Interaction Study With OBE022 5/18/2017
Leap Therapeutics Presents Positive DKN-01 Clinical Data In Biliary Tract Cancers At ASCO 2017 Annual Meeting 5/18/2017
Agios (AGIO) To Present New Clinical Data From Its IDH Programs At ASCO 5/18/2017
Loxo Oncology (LOXO) Announces Details of Two Larotrectinib Clinical Data Oral Presentations at the 2017 ASCO Annual Meeting 5/18/2017
Jounce (JNCE) To Present Phase I Data From JTX-2011 ICONIC Trial At 2017 ASCO Annual Meeting 5/18/2017
miRagen To Present New Clinical Trial Data For MRG-106, An Oligonucleotide Therapeutic Targeting Microrna-155, At The ASCO Annual Meeting 5/18/2017
Egalet Announces ARYMO ER Data Published In Journal Of Opioid Management And American Journal Of Drug And Alcohol Abuse 5/17/2017
Syndax Announces Advancement Of ENCORE 601 In Non-Small Cell Lung Cancer Patients With Disease Progression On Or After PD-1 Therapies 5/17/2017
Alucent Medical Receives FDA Approval To Begin Clinical Trials Of Novel Therapy For Vascular Disease 5/17/2017
Kemwell Biopharma Supplies Biologics Drug Substance For Phase l Clinical Trials For U.S. IND Filing 5/17/2017
Patient Treatment Commences In Cynata’s World First Clinical Trial 5/17/2017
TG Therapeutics (TGTX): Significant Near-Term Catalysts For 2017 5/16/2017
Longeveron Announces Publication Of Phase l Safety And Efficacy Trial Results For Allogeneic Stem Cell Treatment In Frailty Patients 5/16/2017
Sangamo (SGMO) Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Therapy 5/16/2017
Galapagos (GLPG.BR) Release: Seven Abstracts On Filgotinib Accepted By EULAR 2017 5/16/2017
Probiodrug AG Announces Acceptance Of PQ912 Pharmacology Paper By Peer Reviewed Journal 5/16/2017
Adaptimmune (ADAP) Announces Initiation Of Study To Evaluate SPEAR T-Cell Therapy Targeting MAGE-A4 In Multiple Solid Tumors 5/16/2017
Enterin's RASMET Study Enrolls First Patient With Parkinson's Disease 5/16/2017
Kinetic River Receives Phase I SBIR Grant From The NIH 5/16/2017
Teleflex Inc. (TFX) Announces Commencement Of Phase I Clinical Study (FDP-1) Of RePlas Freeze-Dried Plasma 5/15/2017
Glenmark Pharma To Initiate Clinical Study For GBR 1342, Second Investigational New Drug From Immuno-Oncology Portfolio 5/15/2017
Nuvo Pharma Announces Topline Results From European Ankle Sprain Study With Pennsaid 2% 5/15/2017
Advaxis (ADXS) Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac 5/15/2017
Imara Receives Rare Pediatric Disease Designation From FDA For Lead Product Candidate IMR-687 For Sickle Cell Disease 5/15/2017
Syros Pharma Announces First Patient Dosed In Phase I Clinical Trial Of SY-1365, Its First-In-Class Selective CDK7 Inhibitor, In Patients With Advanced Solid Tumors 5/15/2017
Amicus (FOLD) Announces Positive Functional Data From Initial Patients In Pompe Phase I/II Study 5/15/2017
Sangamo (SGMO) Presents Recent Developments From Research And Clinical Programs At Annual Meeting Of The American Society Of Gene & Cell Therapy 5/15/2017
Formation Biologics Announces Dosing Of First Patient In A Phase I/Ila Trial Of AVID100, Closing Of Series B Financing, And Appointment Of Dr. Anthony Tolcher To Its Board Of Directors 5/15/2017
MVRx To Present Outcomes Of Global Clinical Trials For ARTO System At EuroPCR-2017 – May 16-17 5/12/2017
ImmusanT, Inc. Announces Publication Of Positive Data From Phase I Trials Of Nexvax2 In Celiac Disease Patients 5/12/2017
Abeona Therapeutics Announces Top-Line Data For ABO-102 Phase I/II MPS IIIA Gene Therapy Trial At ASGCT 5/12/2017
Loxo Oncology (LOXO) Announces FDA Orphan Drug Designation Granted To Larotrectinib For The Treatment Of Solid Tumors With NTRK-Fusion Proteins 5/12/2017
Selecta (SELB) Commences Dosing In Phase I Clinical Trial Of Nicotine Vaccine For Smoking Cessation And Relapse Prevention 5/12/2017
4 Biotechs That Could Release Stock-Shattering Data Soon 5/11/2017
New MRI Data From Asterias Biotherapeutics' Ongoing SCiStar Clinical Study Indicates AST-OPC1 Cells Prevent Formation Of Damaging Lesion Cavities In Patients Suffering Severe Spinal Cord Injury 5/11/2017
Tocagen Presents Data At The American Society of Gene Therapy 20th Annual Meeting 5/11/2017
AGTC (AGTC) Presents New Data On Its AAV-Based Gene Therapies For The Treatment Of Achromatopsia And X-Linked Retinitis Pigmentosa At The American Society Of Gene And Cell Therapy 20th Annual Meeting 5/11/2017
Zealand Pharma  (ZEAL.CO) Discloses Amylin As The Biological Target Under Their 2014 Agreement With Boehringer Ingelheim 5/11/2017
Sierra Oncology Receives Clearance To Enhance Ongoing Clinical Trials For SRA737 5/10/2017
One Year Follow Up Of Cytori (CYTX) Cell Therapy In Investigator Erectile Dysfunction Trial 5/10/2017
Inovio Pharma (INO) Provides Update On Launch Of Combination Trial For HPV-Associated Head & Neck Cancer 5/10/2017
Longeveron Begins Enrollment Of Second Cohort Of Phase I Trial Of Allogeneic Mesenchymal Stem Cells To Treat Alzheimer's Disease Patients 5/10/2017
Dimension Therapeutics (DMTX) Throws In The Towel On Hemophilia B Drug 5/10/2017
Adaptimmune (ADAP) Announces Initiation Of Study To Evaluate SPEAR T-Cell Therapy Targeting AFP In Liver Cancer 5/10/2017
Loxo Oncology (LOXO) Announces Enrollment Of First Patient In Phase I Clinical Trial For Highly Selective RET Inhibitor, LOXO-292 5/10/2017
Targovax Recruits First Patient Into First ONCOS-102 /Checkpoint Inhibitor Melanoma Study 5/10/2017
Abide Therapeutics Announces Dosing Of First Subject In fMRI Imaging Study To Investigate Brain Activity Patterns Associated With ABX-1431 5/10/2017
3 Cancer Biotechs to Watch at ASCO 5/9/2017
Oncoquest Announces Enrollment Of First Patient In Phase I/II Clinical Study Using Combination Of Oregovomab With Checkpoint Inhibitor Nivolumab In Recurrent Ovarian Cancer 5/9/2017
Biscayne Pharma Readies Phase Ib Trial For Novel Antiepileptic Agent BIS-001 And Receives FDA Orphan Drug Designation For Dravet Syndrome 5/9/2017
Apellis Pharma Receives EMA Orphan Drug Designation For APL-2 In PNH 5/9/2017
Seattle Children's Hospital Release: First-In-Human Clinical Trial Aims To Extend Remission For Children And Young Adults With Leukemia Treated With T-Cell Immunotherapy 5/9/2017
International Stem Cell Corporation Receives Approval To Start Second Patient Cohort In Clinical Trial For Parkinson’s Disease 5/9/2017
Abeona Therapeutics Receives Regulatory Approval To Initiate Clinical Trial In Australia With ABO-102 Gene Therapy For Patients With MPS IIIA 5/9/2017
Protalix (PLX) Announces FDA Investigational New Drug Clearance To Commence Once-Monthly Dosing Study Of Pegunigalsidase Alfa (PRX-102) For The Treatment Of Fabry Disease 5/9/2017
The Lancet Oncology Publishes Phase I Data Demonstrating The Safety, Tolerability, And Preliminary Efficacy Of Cornerstone Pharmaceuticals, Inc.’ CPI-613 In Combination With Modified FOLFIRINOX In Patients With Metastatic Pancreatic Cancer 5/9/2017
Embera NeuroTherapeutics, Inc. Announces Positive Topline Data From Phase Ib Cocaine Interaction Study Of EMB-001 5/8/2017
Araim Pharmaeuticals' Cibinetide (ARA 290) Regenerates Small Nerve Fibers And Improves Neuropathic Clinical Symptoms In The Orphan Disease Of Sarcoidosis 5/8/2017
Fibrocell (FCSC) Announces Data Safety Monitoring Board Recommends Continuation Of Phase I/II Clinical Trial Of FCX-007 For Treatment Of Recessive Dystrophic Epidermolysis Bullosa 5/8/2017
PharmaCyte (PMCB) Updates IND Submission Process In Interview With Facet Life Sciences 5/8/2017
Botanix Commences First Clinical Study For BTX 1503 5/8/2017
4 Biotechs That Could Explode Or Crash In May 5/5/2017
Struggling Zafgen (ZFGN) Catches A Break With Promising Early-Stage Obesity Data 5/5/2017
SGS Life Science Services (SGSN) Clinical Research Announces Results Of First-In-Human Studies Using Novel Virus As Experimental Challenge Agent 5/5/2017
Aclaris (ACRS) Completes Phase I Clinical Trial Of ATI-50001 For The Treatment Of Alopecia Universalis And Alopecia Totalis 5/5/2017
Dauntless Pharma Announces Positive Data From Phase I Study Investigating Octreotide Formulation For Intranasal Delivery 5/4/2017
Hookipa Biotech Presents Positive Data From Phase I First-In-Human Trial Of Vaccine Against Cytomegalovirus 5/4/2017
YiSheng BioPharma Starts China Phase I Trial Of Immuno-Oncology Candidate 5/4/2017
Celsion (CLSN) Updates Clinical Data From The OVATION Study In Newly Diagnosed Advanced Ovarian Cancer Patients 5/4/2017
Fortress Biotech (FBIO) Announces Final Patient Dosed In Phase IB Trial Of CAEL-101 For The Treatment Of AL Amyloidosis 5/4/2017
EyeGate Pharma Submits Investigational Device Exemption (IDE) Filing For Second Pilot Study Of Ocular Bandage Gel 5/4/2017
ContraVir To Advance Second-Generation Formulation Of Tenofovir Exalidex (TXL) For Treatment Of Hepatitis B Virus (HBV) 5/4/2017
EirGenix Scores Phase I Success For Its Leading Biosimilar Product EG12014 5/4/2017
Vical  (VICL) Highlights Successful Outcome Of Phase I Trial Of VL-2397 Novel Antifungal During Its Research And Development Day 5/3/2017
Stealth Biotherapeutics Initiates Phase I/II Trial Of SBT-20 In Patients With Early Stage Huntington's Disease 5/2/2017
ZIOPHARM Oncology (ZIOP) Announces FDA Acceptance Of IND For CD33-Specific CAR-T Cell Therapy Targeting Relapsed/Refractory Acute Myeloid Leukemia 5/2/2017
Abeona Therapeutics Provides Update On EB-101 Gene Therapy For Severe Form Of Epidermolysis Bullosa From The Society For Investigative Dermatology Conference 5/2/2017
Biotech Unicorn Moderna's Vaccine Performs Well in First Human Trial 5/1/2017
YiSheng BioPharma Starts Enrollment In Phase I Immuno-Oncology Clinical Trial Of YS-ON-001 In Patients With Advanced Solid Tumors 5/1/2017
ImmunoGen (IMGN) Announces Results from Mirvetuximab Soravtansine Phase 1 First-in-Human Dose-Escalation Trial Published in Cancer 5/1/2017
The FDA Calls Pfizer (PFE)’s Next-Generation Lung Cancer Drug a Breakthrough 4/28/2017
Nordic Nanovector Release: Updated Results From Phase I/II Trial Of Betalutin In NHL Accepted For Presentation At The International Conference On Malignant Lymphoma In June 4/28/2017
miRagen Presents Interim Results From MRG-201 Phase I Clinical Trial Demonstrating Pharmacodynamic Activity In Human Skin Incisions 4/28/2017
SAGE Therapeutics (SAGE) Announces Initiation Of Phase I Development And First Dosing Of SAGE-718 4/27/2017
ProQR Therapeutics B.V. (PRQR) Announces Clearance Of IND Application To Start Clinical Trial For QR-110 In Leber’s Congenital Amaurosis Type 10 Patients 4/27/2017
Moderna Announces Positive Interim Phase I Clinical Data Demonstrating First mRNA Vaccine Candidate, mRNA-1440, Induces High Levels Of Immunogenicity 4/27/2017
Blaze Bioscience Announces Presentation Of Tumor Paint BLZ-100 Clinical Data At American Society of Breast Surgeons (ASBrS) Annual Meeting 4/27/2017
PIQUR Therapeutics AG Receives EMA Orphan Drug Designation For PQR309 In Diffuse Large B-Cell Lymphoma 4/27/2017
Amazentis Announces Successful Phase IA/IB Study Results In Healthy Elderly Subjects With The Food Metabolite Urolithin A 4/27/2017
First Patient Treated In Turnstone Biologics's Lung Cancer Trial Combining Novel Viral Cancer Therapy With Approved Checkpoint Inhibitor 4/26/2017
Capricor Therapeutics, Inc. Announces Positive Six-Month Results From The Randomized Phase I/II HOPE Clinical Trial In Duchenne Muscular Dystrophy 4/25/2017
Jazz Pharma (JAZZ) Announces Positive Results From The Phase II/III EXPRESS Study Of Xyrem In Pediatric Patients With Narcolepsy With Cataplexy 4/25/2017
Asterias Biotherapeutics Announces Data Monitoring Committee Unanimously Recommends Continuation Of Scistar Phase I/IIa Clinical Trial Of AST-OPC1 For Cervical Spinal Cord Injury 4/25/2017
International Stem Cell Corporation Completes First Cohort In Parkinson's Disease Clinical Trial 4/25/2017
Paratek Pharma (PRTK) Release: Omadacycline Concentrations Exceed Tigecycline Levels In Lungs And Epithelial Lining Fluid According To Pharmacokinetic/Pharmacodynamic (PK/PD) Data 4/25/2017
Voyager Therapeutics (VYGR) Announces Additional Results From Phase Ib Trial Of VY-AADC01 For Advanced Parkinson’s Disease 4/25/2017
AmpliPhi Bio (APHB) Announces Presentation Of Personalized Bacteriophage Therapy Case Study For Life-Threatening Antibiotic-Resistant Infection At Scientific Conference 4/25/2017
Top 15 R&D Spenders In The World For 2017 4/24/2017
Arrowhead Pharma (ARWR) Presents ARC-AAT Clinical Data At The International Liver Congress 4/24/2017
ReViral Announces Good Safety And Pharmacokinetics From Phase I Programme For RSV Antiviral RV521 In Healthy Volunteers 4/24/2017
DURECT (DRRX) Announces Presentation Of Data From A Phase Ib Study Of DUR-928 In Nonalcoholic Steatohepatitis (NASH) At The International Liver Congress 2017 4/24/2017
aTyr Pharma Announces Promising Top-Line Results From Resolaris Phase Ib/II Clinical Trial In Patients With Early Onset Facioscapulohumeral Muscular Dystrophy 4/24/2017
Cara Therapeutics (CARA) Announces Positive Data From Quantitative Phase I Trial Measuring Respiratory Safety Of I.V. CR845 4/24/2017
aTyr Pharma Presents Analyses Of Resolaris Phase Ib/II Trial In Patients With Limb Girdle Muscular Dystrophy 2B And Facioscapulohumeral Muscular Dystrophy At American Academy of Neurology 69th Annual Meeting 4/24/2017
Tiziana Life Sciences Plc Announces Publication Of Peer-Reviewed Paper From Positive Clinical Trial Of Milciclib In Patients With Refractory Solid Tumours 4/21/2017
Atara Biotherapeutics (ATRA) Announces Positive Interim Results from Ongoing Phase I Trial of the Autologous Version of ATA188 in Patients with Primary and Secondary Progressive Multiple Sclerosis (MS) at the American Academy of Neurology Annual Meeting 2017 4/21/2017
Atossa Genetics (ATOS) Receives Positive Interim Review From Independent Safety Committee In Phase I Endoxifen Dose Escalation Study 4/21/2017
Why Former Medivation (MDVN) CEO and a Once-Failed Alzheimer's Drug Could be a Recipe for Disaster for Axovant (AXON) 4/20/2017
NIH Study In The New England Journal of Medicine Shows Novartis AG (NVS) Drug Eltrombopag As First-Line Therapy With Standard Treatment Improves Responses In Severe Aplastic Anemia 4/20/2017
Phase I/II Clinical Trial Of Agenus (AGEN)' Anti-PD-1 Antibody Begins 4/20/2017
Clearside Biomedical (CLSD) Announces Completion Of Patient Enrollment In Phase I/II Open Label Clinical Trial Of CLS-TA In Diabetic Macular Edema 4/20/2017
SIGA (SIGA) Completes Enrollment And Dosing In Final Cohort Of Phase I Study Of IV Formulation Of TPOXX® (Tecovirimat) To Treat Smallpox 4/20/2017
RedHill Biopharma (RDHL) Announces Peer-Reviewed Publication Of The Positive YELIVA Phase I Study Results In Advanced Solid Tumors 4/20/2017
Oral Presentation At EASL Highlights ContraVir’s Tenofovir Exalidex (TXL) Antiviral Activity In Hepatitis B (HBV) Patients 4/20/2017
Mateon Therapeutics (MATN) Announces Initiation Of Investigator-Sponsored Phase I Study Of CA4P In Combination With Everolimus In Neuroendocrine Tumors 4/20/2017
Celsion (CLSN) Announces Presentation Of OVATION Study Findings At The Upcoming ASCO 2017 Annual Meeting 4/20/2017
BTG plc (BTG.L) Release: First European Patients Treated With Dc Bead Lumi Radiopaque Drug-Eluting Beads 4/20/2017
NIH Study In The New England Journal of Medicine Shows Novartis Drug Eltrombopag As First-Line Therapy With Standard Treatment Improves Responses In Severe Aplastic Anemia 4/20/2017
Targovax Initiates First Clinical Trial With TG02, The Second Product From Its RAS-Peptide Immunotherapy Platform 4/20/2017
Arrowhead Pharma (ARWR) Presents ARC-520 And ARC-521 Clinical Data At The International Liver Congress 4/20/2017
Prima Biomed (PRR.AX) Receives Approval For Third Cohort Of Phase I Melanoma Trial 4/20/2017
Prima Biomed (PRR.AX) Receives Approval For Third Cohort Of Phase I Melanoma Trial 4/19/2017
This Year’s Superbug Norovirus Sickens Hundreds of Millions, Prompting Urgent Race for Vaccine 4/18/2017
When It Rains, It Pours: Bay Area's OncoMed (OMED) Tanks Again as Lung Cancer Med Fails Phase II, Discontinues Phase I Study 4/18/2017
BioSpecifics Technologies Corporation (BSTC) Initiates Phase I Clinical Trial Of XIAFLEX For Treatment Of Uterine Fibroids 4/18/2017
Biogen (BIIB) Highlights Advances From Its Neurology Research Programs And Portfolio Of Innovative Medicines At AAN Congress 4/18/2017
Abide Therapeutics Announces Dosing Of First Patient In Phase Ib Study Of ABX-1431 In Tourette Syndrome And Collaboration With Tourette Association Of America 4/18/2017
WCCT Global Release: Ophthalmology Clinical Trial Results Published In Ophthalmology Journal 4/18/2017
Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, LB-100, Reported To Be A Potentiator Of Immunotherapy In An Animal Model 4/18/2017
Medicenna Treats First Patient In Phase IIb Recurrent Glioblastoma Trial 4/13/2017
Immunovaccine Announces Positive Year-Long Immunogenicity Data From Phase I Clinical Trial For Respiratory Syncytial Virus Vaccine Candidate 4/12/2017
NeuralStem Expands Phase I Safety Trial Of NSI-566 Neural Stem Cells In Spinal Injury 4/12/2017
Flugen, Inc. Raises $2M More, Provides Update on Phase I Trial 4/12/2017
3 Drug Giants That Boasts the Best Pipelines 4/11/2017
Eyevensys Receives Approval From The French Product Security Regulatory Agency ANSM To Advance Its Eyecet Platform Into Clinical Development 4/11/2017
Inovio Pharma (INO) Ebola Vaccine Demonstrates Robust Immune Responses With Favorable Safety Profile In Expanded Clinical Trial 4/11/2017
Key Milestone Reached In Catalyst Biosciences’s Subcutaneous Factor IX Program 4/11/2017
Idera Pharma (IDRA) Advances Investigational Treatment—Intratumoral IMO-2125 In Combination With Ipilimumab - For Unmet Need In Anti-PD-1 Refractory Metastatic Melanoma 4/11/2017
Inovio Pharma (INO) Ebola Vaccine Demonstrates Robust Immune Responses With Favorable Safety Profile In Expanded Clinical Trial 4/11/2017
Zika Virus: Themis Initiates Worldwide First Study With Live Attenuated Recombinant Vaccine 4/11/2017
Alexo Announces Initiation Of Phase I Clinical Trial Of ALX148 For The Treatment Of Advanced Solid Tumors And Lymphoma 4/10/2017
Ovid Announces Initiation Of Phase I Clinical Trial Of OV101 For Adolescents With Angelman Syndrome Or Fragile X Syndrome 4/10/2017
Marinus Pharma (MRNS) Release: Ganaxolone IV Clinical Data Presented At Leading International Status Epilepticus Medical Conference 4/10/2017
Kura Oncology Doses First Patient in Phase I Trial of ERK Inhibitor KO-947 4/7/2017
Gazing Into The Crystal Ball For Advaxis (ADXS): What To Expect At ASCO 2017 4/7/2017
Galapagos (GLPG.BR) Doses First Psoriatic Arthritis Patient With Filgotinib 4/6/2017
Asceneuron Receives Regulatory Approval For Phase I Healthy Volunteer Study Of Oral Tau Inhibitor 4/6/2017
Cardiome Pharma Corp. (COM.TO)'s Partner SteadyMed (STDY) Announces Successful Completion Of Trevyent Clinical Validation Study 4/6/2017
China FDA Accepts JHL Biotech's First Clinical Trial Application 4/5/2017
PerkinElmer (PKI) Release: Phase I Clinical Trial Examines Safety Of Using Cord Blood Stem Cells For Treating Children With Autism Spectrum Disorder 4/5/2017
Spyryx Biosciences Presents Data And Corporate Update At Two Recent Conferences In Support Of Clinical Candidate For Cystic Fibrosis 4/5/2017
Agenus (AGEN) Commences Phase I Trial With Neoantigen Cancer Vaccine AutoSynVax 4/5/2017
Agenus (AGEN) Commences Phase I Trial With Neoantigen Cancer Vaccine AutoSynVax 4/5/2017
Novelion (AEGR) Release: Metreleptin And Lipodystrophy Data Presented At The Annual Meeting Of The Endocrine Society 4/5/2017
ASIT Biotech Announces That It Has Achieved The Primary Endpoint Of The Phase I/IIa Clinical Trial With Its hdm-ASIT+ Product Candidate For House Dust Mite Rhinitis 4/5/2017
ABIVAX Initiates Clinical Trial (ABX464-005) To Evaluate The Effect Of ABX464 On HIV-Reservoirs In HIV Patients 4/5/2017
Common Antibiotic May Help To Prevent Or Treat PTSD, University of Zurich Study Reveals 4/4/2017
Sorrento (SRNE) Anti-CEA CAR-T Demonstrates Promising Clinical Activity And Safety In Phase Ib Clinical Trial 4/4/2017
Replicel Life Sciences Release: Positive Results From Replicel's RCS-01 Phase I Skin Trial Are The Company's Most Compelling To Date 4/4/2017
AbbVie (ABBV) Announces Ibrutinib (IMBRUVICA) Supplemental New Drug Application For Previously Treated Chronic Graft-Versus-Host-Disease (Cgvhd) Accepted For Review By U.S. FDA 4/4/2017
Janssen R&D Release: U.S. FDA Accepts For Review The Application Of Ibrutinib (IMBRUVICA) For Chronic Graft-Versus-Host-Disease (Cgvhd) After Failure Of One Or More Lines Of Systemic Therapy 4/4/2017
XBiotech (XBIT) Reports Top-Line Results For 514G3 Antibody Therapy In Serious Staphylococcus Aureus Infections 4/4/2017
Atossa Genetics (ATOS) Enrolls First Cohort Of Eight Subjects In Endoxifen Study 4/4/2017
Corvus Pharma Announces Interim Results From Ongoing Phase I/Ib Study Demonstrating Safety And Clinical Activity Of Lead Checkpoint Inhibitor CPI-444 In Patients With Advanced Cancers 4/4/2017
RedHill Biopharma (RDHL) Receives FDA Orphan Drug Designation For YELIVA For The Treatment Of Cholangiocarcinoma 4/4/2017
Nanobiotix Expands Its Clinical Development In Head And Neck Cancer And I/O 4/4/2017
Bristol-Myers Squibb (BMY)'s Next Big Bet After Opdivo Failure—IDOs 4/4/2017
Biovica Release: DiviTum Results In Blockbuster Drug Study Presented At AACR 4/3/2017
Infinity Pharma (INFI) Release: Updated Phase 1 Data For IPI-549 Presented At AACR Annual Meeting 2017 4/3/2017
ESSA Pharma Provides Clinical Study Update And Announces Presentations At The AACR Annual Meeting 4/3/2017
BeiGene (BGNE) Presents Phase IB Data On RAF Dimer Inhibitor BGB-283 At The 2017 BeiGene (BGNE) Annual Meeting 4/3/2017
Clinical Results Presented From Prothena (PRTA)’s Phase Ib Study Of PRX002/RG7935 Demonstrating Robust Antibody CNS Penetration And Significant Reduction Of Free Serum Alpha-Synuclein In Patients With Parkinson’s Disease 4/3/2017
Bristol-Myers Squibb (BMY) Release: Five-Year Survival Observed With Opdivo (Nivolumab) In Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC), In Phase 1 Study CA209-003 4/3/2017
AXON Neuroscience's Tau Vaccine Offers Potential For Treating Frontotemporal Dementia Patients 4/3/2017